Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Bozic

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Annals of Neurology|March 13, 2010
Reply: To PMID 19798640Carmen Bozic, Julia LaGuette, Alfred Sandrock
Anesthesiology|December 12, 2025
Suzetrigine for the Treatment of Acute Pain: ReplyTodd Bertoch, Carmen Bozic, Scott G Weiner
The New England Journal of Medicine|July 4, 2008
More on melanoma with transdifferentiationMichael A Panzara, Carmen Bozic, Alfred W Sandrock
The New England Journal of Medicine|September 17, 2013
Case reports of PML in patients treated for psoriasisMarianne T Sweetser, Katherine T Dawson, Carmen Bozic
The New England Journal of Medicine|April 26, 2013
Manufacturer's response to case reports of PMLMarianne T Sweetser, Katherine T Dawson, Carmen Bozic
Annals of Neurology|October 3, 2009
Natalizumab and central nervous system lymphoma: no clear associationCarmen Bozic, Julia LaGuette, Michael A Panzara, et al.
Annals of Neurology|December 14, 2011
Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1Carmen Bozic, Sandra Richman, Tatiana Plavina, et al.
Clinical Therapeutics|March 2, 2006
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyBernard Goffe, Kim Papp, David Gratton, et al.
The New England Journal of Medicine|May 18, 2012
Risk of natalizumab-associated progressive multifocal leukoencephalopathyGary Bloomgren, Sandra Richman, Christophe Hotermans, et al.
Annals of Clinical and Translational Neurology|December 11, 2014
Outcome and survival of asymptomatic PML in natalizumab-treated MS patientsTuan Dong-Si, Sandra Richman, Mike P Wattjes, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Annals of Neurology|March 13, 2010
Reply: To PMID 19798640Carmen Bozic, Julia LaGuette, Alfred Sandrock
Anesthesiology|December 12, 2025
Suzetrigine for the Treatment of Acute Pain: ReplyTodd Bertoch, Carmen Bozic, Scott G Weiner
The New England Journal of Medicine|July 4, 2008
More on melanoma with transdifferentiationMichael A Panzara, Carmen Bozic, Alfred W Sandrock
The New England Journal of Medicine|September 17, 2013
Case reports of PML in patients treated for psoriasisMarianne T Sweetser, Katherine T Dawson, Carmen Bozic
The New England Journal of Medicine|April 26, 2013
Manufacturer's response to case reports of PMLMarianne T Sweetser, Katherine T Dawson, Carmen Bozic
Annals of Neurology|October 3, 2009
Natalizumab and central nervous system lymphoma: no clear associationCarmen Bozic, Julia LaGuette, Michael A Panzara, et al.
Annals of Neurology|December 14, 2011
Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1Carmen Bozic, Sandra Richman, Tatiana Plavina, et al.
Clinical Therapeutics|March 2, 2006
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyBernard Goffe, Kim Papp, David Gratton, et al.
The New England Journal of Medicine|May 18, 2012
Risk of natalizumab-associated progressive multifocal leukoencephalopathyGary Bloomgren, Sandra Richman, Christophe Hotermans, et al.
Annals of Clinical and Translational Neurology|December 11, 2014
Outcome and survival of asymptomatic PML in natalizumab-treated MS patientsTuan Dong-Si, Sandra Richman, Mike P Wattjes, et al.
Pageof 2